Tile for Bioera: Consob, after an investigative activity which in November had led to highlighting some "critical issues", certified the non-compliance of the 2022 consolidated financial statements due to non-compliance with various accounting principles.
In particular, the Authority contested the legitimacy of the deconsolidation of the stake in KiGroup starting from January 2021. Obviously sales on the stock on the stock exchange, with Bioera losing 4.55%, after even double-digit drops during the session, to 4, 2 cents, above the November lows of 1.5 cents.
Reproduction reserved © Copyright ANSA